Genetic variation in G-protein-coupled receptors - Consequences for G-protein-coupled receptors as drug targets

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 6, 2005, Pages 1247-1265

  Tang, Chih Min ^a   Insel, Paul A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Classification; Desensitisation; Downregulation; G protein coupled receptors (GPCR); Ligand binding; Orphan receptor; Single nucleotide polymorphism (SNP)

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANGIOTENSIN RECEPTOR; BETA ADRENERGIC RECEPTOR; BRADYKININ RECEPTOR; CALCIUM SENSING RECEPTOR; CHEMOKINE RECEPTOR; DOPAMINE RECEPTOR; ENDOTHELIN RECEPTOR; FOLLITROPIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; LIGAND; MEMBRANE RECEPTOR; MUSCARINIC RECEPTOR; PROSTACYCLIN RECEPTOR; PROTEINASE ACTIVATED RECEPTOR; SEROTONIN RECEPTOR; VASOPRESSIN RECEPTOR;

CELL SURFACE; DIMERIZATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG RESEARCH; DRUG RESPONSE; DRUG TARGETING; DRUG USE; GENE DELETION; GENE INSERTION; GENE LOCUS; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; INTRACELLULAR TRANSPORT; LIGAND BINDING; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FOLDING; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; REVIEW; RNA TRANSLATION; SINGLE NUCLEOTIDE POLYMORPHISM;

DRUG DELIVERY SYSTEMS; HUMANS; POLYMORPHISM, GENETIC; RECEPTORS, G-PROTEIN-COUPLED; VARIATION (GENETICS);

EID: 28844478334     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.6.1247     Document Type: Review

References (156)

1. WANG X, TOMSO DJ, LIU X, BELL DA: Single nucleotide polymorphism in transcriptional regulatory regions and expression of environmentally responsive genes. Toxicol. Appl. Pharmacol. (2005) 207(2 Suppl.):84-90.
2. BOCKAERT J, DUMUIS A, FAGNI L, MARIN P: GPCR-GIP networks: a first step in the discovery of new therapeutic drugs? Curr. Opin. Drug Discov. Devel. (2004) 7(5):649-657.
3. VENTER JC, ADAMS MD, MYERS EW et al.: The sequence of the human genome. Science (2001) 291(5507):1304-1351.
4. INTERNATIONAL HUMAN GENOME SEQUENCING CONSORTIUM: Finishing the euchromatic sequence of the human genome. Nature (2004) 431(7011):931-945.
5. VASSILATIS DK, HOHMANN JG, ZENG H et al.: The G protein-coupled receptor repertoires of human and mouse. Proc. Natl. Acad. Sci. USA (2003) 100(8):4903-4908.
6. SCHIOTH HB, FREDRIKSSON R, The GRAFS classification system of G-protein coupled receptors in comparative perspective. Gen. Comp. Endocrinol. (2005) 142(1-2):94-101.
7. FREDRIKSSON R, SCHIOTH HB: The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol. Pharmacol. (2005) 67(5):1414-1425.
8. FOORD SM, BONNER TI, NEUBIG RR et al.: International Union of Pharmacology. XLVI. G protein-coupled receptor list, Pharmacol. Rev. (2005) 57(2):279-288.
9. CIVELLI O: GPCR deorphanizations: the novel, the known and the unexpected transmitters. Trends Pharmacol. Sci. (2005) 26(1):15-19.
10. SAKMAR TP, MENON ST. MARIN EP, AWAD ES: Rhodopsin: insights from recent structural studies. Ann. Rev. Biophys. Biomol. Struct. (2002) 31:443-484.
11. FERGUSON SS: Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. (2001) 53(1):1-24.
12. KRISTIANSEN K: Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol. Ther. (2004) 103(1):21-80.
13. LEFKOWITZ RJ: Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol. Sci. (2004) 25(8):413-422.
14. MAUDSLEY S, MARTIN B, LUTTRELL LM: The origins of diversity and specificity in g protein-coupled receptor signaling. J. Pharmacol. Exp. Ther. (2005) 314(2):495-494.
15. VAUQUELIN G, VAN LIEFDE I: G protein-coupled receptors: a count of 1001 conformations. Fundam. Ciin. Pharmacol. (2005) 19(1):45-56.
16. MCCUDDEN CR, HAINS MD, KIMPLE RJ, SIDEROVSKI DP, WILLARD FS: G-protein signaling: back to the future. Cell. Mol. Life Sci. (2005) 62(5):551-577.
17. RIDDLE EL, SCHWARTZMAN RA, BOND M, INSEL PA: Multi-tasking RGS proteins in the heart: the next therapeutic target? Circ. Res. (2005) 96(4):401-411.
18. NEVES SR, RAM PT, IYENGAR R: G protein pathways. Science (2002) 296(5573):1636-1639.
19. KUROSE H: Galpha12 and Galpha13 as key regulatory mediator in signal transduction. Life Sci. (2003) 74(2-3):155-16L
20. RIOBO NA, MANNING DR: Receptors coupled to heterotrimeric G proteins of the G12 family. Trends Pharmacol. Sci. (2005) 26(3):146-154.
21. MAILLET M, ROBERT SJ, CACQUEVEL M et al.: Crosstalk between Rap1 and Rac regulates secretion of sAPPalpha. Nat. Cell. Biol. (2003) 5(7):633-639.
22. RANGARAJAN S, ENSERINK JM. KUIPERIJ HB et al.: Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the beta 2-adrenergic receptor. J. Cell Biol. (2003) 160(4):487-493.
23. WONG LF, POLSON JW, MURPHY D, PATON JF, KASPAROV S: Genetic and pharmacological dissection of pathways involved in the angiotensin II-mediated depression of baroreflex function. FASEB J. (2002) 16(12):1595-1601.
24. KOLAKOWSKI LF, JR.: GCRDb: a G-protein-coupled receptor database. Receptors Channels (1994) 2(1):1-7.
25. FAN QR, HENDRICKSON WA: Structure of human follicle-stimulating hormone in complex with its receptor. Nature (2005) 433(7023):269-277.
26. BOCKAERT J, PIN JP: Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. (1999) 18(7):1723-1729.
27. FREDRIKSSON R, LAGERSTROM MC, LUNDIN LG, SCHIOTH HB: The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. (2003) 63(6):1256-1272.
28. DORIS PA: Hypertension genetics, single nucleotide polymorphisms, and the common disease:common variant hypothesis. Hypertension (2002) 39(2 Pt 2):323-331.
29. SMALL KM, MCGRAW DW, LIGGETT SB: Pharmacology and physiology of human adrenergic receptor polymorphisms. Ann. Rev. Pharmacol. Toxicol. (2003) 43:381-411.
30. SADEE W, HOEG E, LUCAS J, WANG D: Genetic variations in human G protein-coupled receptors: implications for drug therapy. AAPS PharmSci. (2001) 3(3):E22.
31. KIRSTEIN SL, INSEL PA: Autonomic nervous system pharmacogenomics: a progress report. Pharmacol. Rev. (2004) 56(1):31-52.
32. PEREZ DM, KARNIK SS: Multiple signaling states of G-protein-coupled receptors. Pharmacol. Rev. (2005) 57(2):147-161.
33. BULENGER S, MARULLO S, BOUVIER M: Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol. Sci. (2005) 26(3):131-137.
34. RANA BK, SHIINA T, INSEL PA. Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications. Ann. Rev. Pharmacol. Toxicol. (2001) 41:593-624.
35. O'BRIEN SJ, NELSON GW: Human genes that limit AIDS. Nat. Genet. (2004) 36(6):565-574.
36. WINKLER C, AN P, O'BRIEN SJ: Patterns of ethnic diversity among the genes that influence AIDS. Hum. Mol. Genet. (2004) 13(Spec. No. 1):R9-R19.
37. COAKLEY E, PETROPOULOS CJ, WHITCOMB JM: Assessing chemokine co-receptor usage in HIV. Curr. Opin. Infect. Dis. (2005) 18(1):9-15.
38. MCDERMOTT DH, ZIMMERMAN PA, GUIGNARD F, KLEEBERGER CA, LEITMAN SF, MURPHY PM: CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet (1998) 352(9131):866-870.
39. ERDMANN J, HEGEMANN N, WEIDEMANN A et al.: Screening the human bradykinin B2 receptor gene in patients with cardiovascular diseases: identification of a functional mutation in the promoter and a new coding variant (T21M). Am. J. Med. Genet. (1998) 80(5):521-525.
40. ZHANG Y, ZHANG KX, WANG GL, HUANG W, ZHU DL: Angiotensin II Type 2 receptor gene polymorphisms and essential hypertension. Acta Pharmacol. Sin. (2003) 24(11):1089-1093.
41. SMALL KM, MIALET-PEREZ J, SEMAN CA, THEISS CT, BROWN KM, LIGGETT SB: Polymorphisms of cardiac presynaptic alpha2C adrenergic receptors: Diverse intragenic variability with haplotype-specific functional effects. Proc. Natl. Acad, Sci. USA (2004) 101(35):13020-13025.
42. SMALL KM, WAGONER LE, LEVIN AM, KARDIA SL, LIGGETT SB: Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. (2002) 347(15):1135-1142.
43. ARINAMI T, GAO M, HAMAGUCHI H, TORU M: A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum. Mol. Genet. (1997) 6(4):577-582.
44. BREEN G, BROWN J, MAUDE S et al: -141 C del/ins polymorphism of the dopamine receptor 2 gene is associated with schizophrenia in a British population. Am. J. Med. Genet. (1999) 88(4):407-410.
45. OKUYAMA Y, ISHIGURO H, TORU M, ARINAMI T. A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochem. Biophys. Res. Commun. (1999) 258(2):292-295.
46. STEFANIS NC, BRESNICK JN, KERWIN RW, SCHOFIELD WN, MCALLISTER G: Elevation of D4 dopamine receptor mRNA in postmortem schizophrenic brain. Brain Res. Mol. Brain Res. (1998) 53(1-2):112-119.
47. PAROLA AL, KOBILKA BK: The peptide product of a 5′ leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis. J. Biol. Chem. (1994) 269(6):4497-4505.
48. MCGRAW DW, FORBES SL, KRAMER LA, LIGGETT SB: Polymorphisms of the 5′ leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J. Clin. Invest. (1998) 102(11):1927-1932.
49. SIVAGNANASUNDARAM S, MORRIS AG, GAITONDE EJ, MCKENNA PJ, MOLLON JD, HUNT DM: A cluster of single nucleotide polymorphisms in the 5′-leader of the human dopamine D3 receptor gene (DRD3) and its relationship to schizophrenia. Neurosci. Lett. (2000) 279(1):13-16.
50. DRYSDALE CM, MCGRAW DW, STACK CB et al.: Complex promoter and coding region beta 2-adrenergic receptor haplotypes after receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. USA (2000) 97(19):10483-10488.
51. YAMADA K, ISHIYAMA-SHIGEMOTO S, ICHIKAWA F et al.: Polymorphism in the 5′-leader cistron of the beta2-adrenergic receptor gene associated with obesity and Type 2 diabetes. J. Clin. Endocrinol. Metab. (1999) 84(5):1754-1757.
52. CONNE B, STUTZ A, VASSALLI JD: The 3′ untfanslated region of messenger RNA: A molecular 'hotspot' for pathology? Nat. Med, (2000) 6(6):637-641.
53. SZOMBATHY T, SZALAI C, KATALIN B, PALICZ T, ROMICS L, CSASZAR A. Association of angiotensin II Type 1 receptor polymorphism with resistant essential hypertension. Clin. Chim. Acta. (1998) 269(1):91-100.
54. BONNARDEAUX A, DAVIES E, JEUNEMAITRE X et al.: Angiotensin II Type 1 receptor gene polymorphisms in human essential hypertension. Hypertension (1994) 24(1):63-69.
55. WANG WY, ZEE RY, MORRIS BJ: Association of angiotensin II Type 1 receptor gene polymorphism with essential hypertension. Clin. Genet. (1997) 51001-34.
56. MILLER JA, THAI K, SCHOLEY JW- Angiotensin II Type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int. (1999) 56(6):2173-2180.
57. ALVAREZ R, REGUERO JR, BATALLA A et al.: Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. Cardiovasc. Res. (1998) 40(2):375-379.
58. FINCKH U, ROMMELSPACHER H, KUHN S et al.: Influence of the dopamine D2 receptor (DRD2) genotype on neuroadaptive effects of alcohol and the clinical outcome of alcoholism. Pharmacogenetics. (1997) 7(4):271-281.
59. DE LUCA V, VINCENT JB, MULLER DJ et al.: Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. Pharmacol. Res. (2005) 51(4):381-384.
60. ELSHOURBAGY NA, ADAMOU JE, GAGNON AW, WU HL, PULLEN M, NAMBI P: Molecular characterization of a novel human endothelin receptor splice variant. J. Biol. Chem. (1996) 271(41):25300-25307.
61. ODA Y, TU CL, PILLAI S, BIKLE DD: The calcium sensing receptor and its alternatively spliced form in keratinocyte differentiation. J. Biol. Chem. (1998) 273(36):23344-23352.
62. CLAEYSEN S, SEBBEN M, BECAMEL C, BOCKAERT J, DUMUIS A. Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol. Pharmacol. (1999) 55(5):910-920.
63. BOCKAERT J, CLAEYSEN S, SEBBEN M, DUMUIS A: 5-HT4 receptors; gene, transduction and effects on olfactory memory. Ann. NY Acad Sci. (1998) 861:1-15.
64. SCHMAUSS C: Regulation of serotonin 2C receptor pre-mRNA editing by serotonin. Int. Rev. Neurobiol. (2005) 63:83-100.
65. BURNS CM, CHU H, RUETER SM et al.: Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature (1997) 387(6630):303-308.
66. NISWENDER CM, COPELAND SC, HERRICK-DAVIS K, EMESON RB, SANDERS-BUSH E: RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J. Biol. Chem. (1999) 274(14):9472-9478.
67. MCGREW L, PRICE RD, RACKLER E, CHANG MS, SANDERS-BUSH E: RNA editing of the human serotonin 5-HT2C receptor disrupts transactivation of the small G-protein RhoA. Mol. Pharmacol. (2004) 65(1):252-256.
68. DUVERNAY MT, FILIPEANU CM, WU G: The regulatory mechanisms of export trafficking of G protein-coupled receptors. Cell. Signal. (2005) 17(12):1457-1465.
69. BUNGE S, WEDEMANN H, DAVID D et al.: Molecular analysis and genetic mapping of the rhodopsin gene in families with autosomal dominant retinitis pigmentosa. Genomics (1993) 17(1):230-233.
70. SULLIVAN LJ, MAKRIS GS, DICKINSON P et al.: A new codon 15 rhodopsin gene mutation in autosomal dominant retinitis pigmentosa is associated with sectorial disease. Arch. Ophthalmol. (1993) 111(11):1512-1517.
71. BOND C, LAFORGE KS, TIAN M et al.: Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl. Acad. Sci. USA (1998) 95(16):9608-9613.
72. OKSCHE A, ROSENTHAL W: The molecular basis of nephrogenic diabetes insipidus. J. Mol. Med. (1998) 76(5):326-337.
73. TSUKAGUCHI H, MATSUBARA H, TAKETANUI S, MORI Y, SEIDO T, INADA M: Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin Type 2 receptor in patients with X-linked nephrogenic diabetes insipidus. J. Clin. Invest. (1995) 96(4):2043-2050.
74. HEBERT TE, MOFFETT S, MORELLO JP et al.: A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J. Biol. Chem. (1996) 271(27):16384-16392.
75. BAI M, TRIVEDI S, BROWN EM: Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of CaR-transfectcd HEK293 cells. J. Biol. Chem. (1998) 273(36):23605-23610.
76. DE LUCA F, RAY K, MANCILLA EE et al.: Sporadic hypoparathyroidism caused by de novo gain-of-function mutations of the Ca(2+)-sensing receptor. J. Clin. Endocrinol. Metab. (1997) 82(8):2710-2715.
77. WATANABE T, BAI M, LANE CR et al.: Familial hypoparathyroidism: identification of a novel gain of function mutation in transmembrane domain 5 of the calcium-sensing receptor. J. Clin. Endocrinol. Metab. (1998) 83(7):2497-2502.
78. GAINETDINOV RR, PREMONT RT, BOHN LM, LEFKOWITZ RJ, CARON MG: Desensitization of G protein-coupled receptors and neuronal functions. Ann. Rev. Neurosci. (2004) 27:107-144.
79. HAZELWOOD LA, SANDERS-BUSH E: His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation. Mol. Pharmacol. (2004) 66(5):1293-1300.
80. SMALL KM, BROWN KM, FORBES SL, LIGGETT SB: Polymorphic deletion of three intracellular acidic residues of the alpha 2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization. J. Biol. Chem. (2001) 276(7):4917-4922.
81. BRUCK H, LEINEWEBER K, BUSCHER R et al.: The Gln27Glu beta2-adrenoceptor polymorphism slows the onset of desensitization of cardiac functional responses in vivo. Pharmacogeneties (2003) 13(2):59-66.
82. BRUCK H, LEINEWEBER K, ULRICH A et al.: Thr164Ile polymorphism of the human beta2-adrenoceptor exhibits blunted desensitization of cardiac functional responses in vivo. Am. J. Pbysiol, Heart Circ. Physiol. (2003) 285(5):H2034-H2038.
83. ROTONDO A, NIELSEN DA, NAKHAI B, HULIHAN-GIBLIN B, BOLOS A, GOLDMAN D: Agonist-promoted down-regulation and functional desensitization in two naturally occurring variants of the human serotonin1A receptor. Neuropsychopharmacology (1997) 17(1):18-26.
84. GREEN SA, TURKI J, BEJARANO P, HALL IP, LIGGETT SB: Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. (1995) 13(1):25-33.
85. GREEN SA, TURKI J, INNIS M, LIGGETT SB: Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry (1994) 33(32):9414-9419.
86. BUSCHER R, EILMES KJ, GRASEMANN H et al.: beta2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease. Pharmacogenetics (2002) 12(5):347-353.
87. BRODDE OE, LEINEWEBER K: Beta2-adrenoceptor gene polymorphisms. Pharmacogenet. Genomics (2005) 15(5):267-275.
88. ISRAEL E, CHINCHILLI VM, FORD JG et al.: Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet (2004) 364(9444):1505-1512.
89. KENAKIN T: Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol. Pharmacol. (2004) 65(1):2-11.
90. KOPP P, VAN SANDE J, PARMA J et al.: Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N. Engl. J. Med. (1995) 332(3):150-154.
91. HOLZAPFEL HP, FUHRER D, WONEROW P, WEINLAND G, SCHERBAUM VA, PASCHKE R: Identification of constitutively activating somatic thyrotropin receptor mutations in a subset of toxic multinodular goiters. J. Clin. Endocrinol. Metab. (1997) 82(12):4229-4233.
92. OKADA M, NORTHUP JK, OZAKI N, RUSSELL JT, LINNOILA M, GOLDMAN D: Modification of human 5-HT(2C) receptor function by Cys23Ser, an abundant, naturally occurring aminoacid substitution. Mol. Psychiatry (2004) 9(1):55-64.
93. SODHI MS, ARRANZ MJ, CURTIS D et al.: Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport (1995) 7(1):169-172.
94. LIU IS, SEEMAN P, SANYAL S et al.: Dopamine D4 receptor variant in Africans, D4valine194glycine, is insensitive to dopamine and clozapine: report of a homozygous individual. Am. J. Med. Genet. (1996) 61(3):277-282.
95. OKAZAKI R, CHIKATSU N, NAKATSU M et al.: A novel activating mutation in calcium-sensing receptor gene associated with a family of autosomal dominant hypocalcemia. J. Clin. Endocrinol. Metab. (1999) 84(1):363-366.
96. PUFFENBERGER EG, HOSODA K, WASHINGTON SS et al.: A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell (1994) 79(7):1257-1266.
97. ROSENTHAL W, SEIBOLD A, ANTARAMMN A et al.: Mutations in the vasopressin V2 receptor gene in families with nephrogenic diabetes insipidus and functional expression of the Q-2 mutant. Celll. Mol. Biol. (Noisy-le-grand). (1994) 40(3):429-436.
98. KOTLAR TJ, YOUNG RH, ALBANESE C, CROWLEY WF, JR., SCULLY RE, JAMESON JL: A mutation in the follicle-stimulating hormone receptor occurs frequently in human ovarian sex cord tumors. J. Clin. Endocrinol. Metab. (1997) 82(4):1020-1026.
99. OSTROM RS, POST SR, INSEL PA: Stoichiometry and compartmentation in G protein-coupled receptor signaling: implications for therapeutic interventions involving G(s). J. Pharmacol. Exp. Ther. (2000) 294(2):407-412.
100. LEFKOWITZ RJ, SHENOY SK: Transduction of receptor signals by beta-arrestins. Science (2005) 308(5721):512-517.
101. LAITINEN T, POLVI A, RYDMAN P et al.: Characterization of a common susceptibility locus for asthma-related traits. Science (2004) 304(5668):300-304.
102. MELEN E, BRUCE S, DOEKES G et al.: Haplorypes of G protein-coupled receptor 154 are associated with childhood allergy and asthma. Am. J. Respir. Crit. Care Med. (2005) 171(10):1089-1095.
103. ITOH Y, KAWAMATA Y, HARADA M et al.: Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature (2003) 422(6928):173-176.
104. HAMID YH, VISSING H, HOLST B et al.: Studies of relationships between variation of the human G protein-coupled receptor 40 Gene and Type 2 diabetes and insulin release. Diabet. Med. (2005) 22(1):74-80.
105. OGAWA T, HIROSE H, MIYASHITA K, SAITO I, SARUTA T: GPR40 gene Arg211His polymorphism may contribute to the variation of insulin secretory capacity in Japanese men. Metabolism (2005) 54(3):296-299.
106. THOMSON PA, WRAY NR, THOMSON AM et al.: Sex-specific association between bipolar affective disorder in women and GPR50, an X-linked orphan G protein-coupled receptor. Mol. Psychiatry (2005) 10(5):470-478.
107. DE ROUX N, GENIN E, CAREL JC, MATSUDA F, CHAUSSAIN JL, MILGROM E: Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc. Natl. Acad. Sci. USA (2003) 100(19):10972-10976.
108. SEMINARA SB, MESSAGER S, CHATZIDAKI EE et al.: The GPR54 gene as a regulator of puberty. N. Engl. J. Med. (2003) 349(17):1614-1627.
109. SEMPLE RK, ACHERMANN JC, ELLERY J et al.: Two novel missense mutations in g protein-coupled receptor 54 in a patient with hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. (2005) 90(3):1849-1855.
110. TATTERSFIELD AE, HALL IP: Are beta2-adrenoceptor polymorphisms important in asthma-an unravelling story. Lancet (2004) 364(9444):1464-1466.
111. MUSZKAT M, STEIN CM: Pharmacogenetics and response to beta-adrenergic receptor antagonists in heart failure. Clin. Pharmacol. Ther. (2005) 77(3):123-126.
112. TANG CM, HOERNING A, BUSCHER R et al.: Human adenosine 2B receptor: SNP discovery and evaluation of expression in patients with cystic fibrosis. Pharmacogenet. Genomics (2005) 15(5):321-327.
113. XIE HG, KIM RB, WOOD AJ, STEIN CM: Molecular basis of ethnic differences in drug disposition and response. Ann. Rev. Pharmacol. Toxicol. (2001) 41:815-850.
114. WILSON JH, WENSEL TG: The nature of dominant mutations of rhodopsin and implications for gene therapy. Mol. Neurobiol, (2003) 28(2):149-158.
115. TANG CM, INSEL PA: GPCR expression in the heart; 'new' receptors in myocytes and fibroblasts. Trends Cardiovasc. Med. (2004) 14(3):94-99.
116. LEMONDE S, DU L, BAKISH D, HRDINA P, ALBERT PR: Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int. J. Neuropsychopharmacol. (2004) 7(4):501-506.
117. BRUSS M, BONISCH H, BUHLEN M, NOTHEN MM, PROPPING P, GOTHERT M: Modified ligand binding to the naturally occurring Cys-124 variant of the human serotonin 5-HT1B receptor. Pharmacogenetics (1999) 9(1):95-102.
118. OZAKI N, MANJI H, LUBIERMAN V et al.: A naturally occurring amino acid substitution of the human serotonin 5-HT2A receptor influences amplitude and timing of intracellular calcium mobilization. J. Neurochem. (1997) 68(5):2186-2193.
119. ARRANZ MJ, MUNRO J, BIRKETT J et al.: Pharmacogenetic prediction of clozapine response. Lancet (2000) 355(9215):1615-1616.
120. AUBERT R, BETOULLE D, HERBETH B, SIEST G, FUMERON F: 5-HT2A receptor gene polymorphism is associated with food and alcohol intake in obese people. Int. J. Obes. (2000) 24(7):920-924.
121. HERBETH B, AUBRY E, FUMERON F et al.: Polymorphism of the 5-HT2A receptor gene and food intakes in children and adolescents: the Stanislas Family Study. Am. J. Clin. Nutr. (2005) 82(2):467-470.
122. HOLMES C, ARRANZ MJ, POWELL JF, COLLIER DA, LOVESTONE S: 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum. Mol. Genet. (1998) 7(9):1507-1509.
123. YUAN X, YAMADA K, ISHIYAMA-SHIGEMOTO S, KOYAMA W, NONAKA K. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and Type II diabetes. Diabetologia (2000) 43(3):373-376.
124. SMALL KM, FORBES SL, BROWN KM, LIGGETT SB: An asn to lys polymorphism in the third intracellular loop of the human alpha 2A-adrenergic receptor imparts enhanced agonist-promoted Gi coupling. J. Biol. Chem. (2000) 275(49):38518-38523.
125. SMALL KM, FORBES SL, RAHMAN FF, BRIDGES KM, LIGGETT SB: A four amino acid deletion polymorphisin in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J. Biol. Chem. (2000) 275(30);23059-23064.
126. RATHZ DA, BROWN KM, KRAMER LA, LIGGETT SB: Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J. Cardiovasc. Pharmacol. (2002) 39(2):155-160.
127. MASON DA, MOORE JD, GREEN SA, LIGGETT SB: A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J. Biol. Chem. (1999) 274(18):12670-12674.
128. MARTINEZ FD, GRAVES PE, BALDINI M, SOLOMON S, ERICKSON R: Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. (1997) 100(12):3184-3188.
129. ISAZA C, HENAO J, RAMIREZ E, CUESTA F, CACABELOS R: Polymorphic variants of the beta2-adrenergic receptor (ADRB2) gene and ADRB2-related propanolol-induced dyslipidemia in the Colombian population. Meth. Find. Exp. Clin. Pharmacol. (2005) 27(4):237-244.
130. GREEN SA, COLE G, JACINTO M, INNIS M, LIGGETT SB: A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J. Biol. Chem. (1993) 268(31):23116-23121.
131. MITCHELL BD, BLANGERO J, COMUZZIE AG et al.: A paired sibling analysis of the beta-3 adrenergic receptor and obesity in Mexican Americans. J. Clin. Invest. (1998) 101(3):584-587.
132. ALVAREZ-HERNANDEZ D, SANTAMARIA I, RODRIGUEZ-GARCIA M, IGLESIAS P, DELGADO-LILLO R, CANNATA-ANDIA JB: A novel mutation in the calcium-sensing receptor responsible for autosomal dominant hypocalcemia in a family with two uncommon parathyroid hormone polymorphisms. J. Mol. Endocrinol. (2003) 31(2):255-262.
133. UCKUN-KITAPCI A, UNDERWOOD LE, ZHANG J, MOATS-STAATS B: A novel mutation (E767K) in the second extracellular loop of the calcium sensing receptor in a family with autosomal dominant hypocalcemia. Am. J. Med. Genet. A. (2005) 132(2):125-129,
134. MARCHAL-VICTORION S, VIONNET N, ESCRIEUT C et al.: Genetic, pharmacological and functional analysis of cholecystokinin-1 and cholecystokinin-2 receptor polymorphism in Type 2 diabetes and obese patients. Pharmacogenetics (2002) 12(1):23-30.
135. SMITH MW, DEAN M, CARRINGTON M et al.: Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science (1997) 277(5328):959-965.
136. O'BRIEN TR, MCDERMOTT DH, IOANNIDIS JP et al.: Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS (2000) 14(7):821-826.
137. BREAM JH, YOUNG HA, RICE N et al.: CCR5 promoter alleles and specific DNA binding factors. Science (1999) 284(5412):223.
138. SAMSON M, LIBERT F, DORANZ BJ et al.: Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 382(6593):722-725.
139. HUANG JL, GAO PS, MATHIAS RA et al.: Sequence variants of the gene encoding chemoattractant receptor expressed on Th2 cells (CRTH2) are associated with asthma and differentially influence mRNA stability. Hum. Mol. Genet. (2004) 13(21):2691-2697.
140. CRAVCHIK A, SIBLEY DR, GEJMAN PV: Functional analysis of the human D2 dopamine receptor missense variants. J. Biol. Chem. (1996) 271(42):26013-26017.
141. CRAVCHIK A, SIBLEY DR, GEJMAN PV: Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants. Pharmacogenetics (1999) 9(1):17-23.
142. TANAKA H, MOROI K, IWAI J et al.: Novel mutations of the endothelin B receptor gene in patients with Hirschsprung's disease and their characterization. J. Biol. Chem. (1998) 273(18):11378-11383.
143. GROMOLL J, SIMONI M, NORDHOFF V, BEHRE HM, DE GEYTER C, NIESCHLAG E: Functional and clinical consequences of mutations in the FSH receptor. Mol. Cell Endocrinol. (1996) 125(1-2):177-182.
144. SIMONI M, NIESCHLAG E, GROMOLL J: Isoforms and single nucleotide polymorphisms of the FSH receptor gene: implications for human reproduction. Hum. Reprod. Update (2002) 8(5):413-421.
145. FALCONER H, ANDERSSON E, AANESEN A, FRIED G: Follicle-stimulating hormone receptor polymorphisms in a population of infertile women. Acta Obstet. Gynecol. Scand. (2005) 84(8):806-811.
146. STITHAM J, STOJANOVIC A, HWA J: Impaired receptor binding and activation associated with a human prostacyclin receptor polymorphism. J. Biol. Chem. (2002) 277(18):15439-15444.
147. DONFACK J, KOGUT P, FORSYTHE S, SOLWAYJ, OBER C: Sequence variation in the promoter region of the cholinergic receptor muscarinic 3 gene and asthma and atopy. J. Allergy Clin. Immunol. (2003) 111(3):527-532.
148. WANG D, QUILLAN JM, WINANS K, LUCAS JL, SADEE W: Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding. J. Biol. Chem. (2001) 276(37):34624-34630.
149. COMPTON SJ, CAIRNS JA, PALMER KJ, AL-ANI B, HOLLENBERG MD, WALLS AF: A polymorphic protease-activated receptor 2 (PAR2) displaying reduced sensitivity to trypsin and differential responses to PAR agonists. J. Biol. Chem. (2000) 275(50):39207-39212.
150. JANSSENS R, PAINDAVOINE P, PARMENTIER M, BOEYNAEMS JM: Human P2Y2 receptor polymorphism: identification and pharmacological characterization of two allelic variants. Br. J. Pharmacol. (1999) 127(3):709-716.
151. HOLLOPETER G, JANTZEN HM, VINCENT D et al.: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature (2001) 409(6817):202-207.
152. TENG Y, TIAN H, WANG H et al.: Mutation identification in a 5-generation pedigree with autosomal dominant retinitis pigmentosa. J. Huazhong Univ. Sci. Technolog. Med. Sci. (2003) 23(3):242-244, 253.
153. SUNG CH, DAVENPORT CM, HENNESSEY JC et al.: Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Proc. Natl. Acad. Sci. USA (1991) 88(15):6481-6485.
154. YONG RY, CHEE CK, YAP EP: A two-stage approach identifies a Q344X mutation in the rhodopsin gene of a Chinese Singaporean family with autosomal dominant retinitis pigmentosa. Ann. Acad Med. Singapore (2005) 34(1):94-99.
155. BIRNBAUMER M, GILBERT S, ROSENTHAL W: An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs/adenylyl cyclase system. Mol. Endocrinol. (1994) 8(7):886-894.
156. SAUER CG, WHITE K, STOHR H et al.: Evaluation of the G protein coupled receptor-75 (GPR75) in age related macular degeneration. Br. J. Ophthalmol. (2001) 85(8):969-975.